ASC30
Ascletis Pharma's oral small-molecule GLP-1 receptor agonist, now in two global phase 3 obesity trials enrolling about 4,600 people. It exists in two formulations that are easy to confuse — a once-daily tablet and a subcutaneous depot with a half-life measured in weeks — and every efficacy number published for it so far is placebo-adjusted and sponsor-reported.
ASC30 is an experimental once-daily weight-loss pill — a non-peptide drug that switches on the same receptor as Ozempic and Wegovy. It is designed to trigger only the helpful half of that receptor's signalling, with the goal of causing less nausea. In a 13-week study it produced about 7.7% more weight loss than placebo at the top dose, and it is now in large final-stage trials. All the results so far come from the company, not from published papers.
What is ASC30?
ASC30 is Ascletis Pharma's investigational GLP-1 receptor agonist for obesity and type 2 diabetes. It is genuinely a small molecule rather than a peptide — it appears in this catalogue for the same reason orforglipron does, because it competes directly with peptide GLP-1 agonists and a reader comparing options will encounter it alongside them. Two things distinguish it. The first is the signalling claim: Ascletis describes ASC30 as a fully biased GLP-1 receptor agonist without β-arrestin recruitment, the idea being that cAMP signalling carries the metabolic benefit while β-arrestin recruitment contributes to receptor desensitisation and some of the gastrointestinal burden. The second is that ASC30 is being developed in two formulations at once — a once-daily oral tablet, which is the formulation in phase 3, and an ultra-long-acting subcutaneous depot whose reported half-life runs to several weeks. These are not interchangeable and their reported results should never be quoted together. As of late October 2026 the oral programme is in two recruiting global phase 3 trials, AURORA-1 and AURORA-2, which between them plan to enrol roughly 4,600 participants with readouts guided to 2028. Nothing about ASC30 has been published in a peer-reviewed journal; the evidence base is conference abstracts, a conference poster and company announcements.
What ASC30 Is Investigated For
ASC30's case rests on two completed randomised phase 2 studies, both reported by the sponsor rather than published. In the 13-week oral phase 2a (125 participants, mean baseline weight 107.3 kg, mean BMI 38.6, no diabetes), placebo-adjusted mean body-weight reduction was 5.4% at 20 mg, 7.0% at 40 mg and 7.7% at 60 mg, all at p<0.0001, with no observed weight-loss plateau. At 60 mg, 80.0% of participants lost at least 5% of body weight against 4.2% on placebo, and 45.0% lost at least 7% against 4.2%. In the subcutaneous depot phase 2 portion (65 participants, three monthly 400 mg doses and no titration), placebo-adjusted loss was 6.3% at week 12 and 7.5% at week 16, with 5.8% still separating from placebo at week 24 — four months after the final injection. Three caveats shape how much that is worth. Every efficacy figure released is placebo-adjusted, so absolute weight change is unknown. None of it is peer-reviewed; the sources are company announcements, American Diabetes Association abstracts and an ObesityWeek poster. And the phase 2 trial in type 2 diabetes completed in August 2026 with no topline announced as of late October, while the phase 3 programme that includes a diabetes-inclusive arm started before that readout would have been public. The competitive position is harder than it was when this programme began. Orforglipron was approved in April 2026 and oral semaglutide 25 mg in December 2025, so ASC30 is no longer competing to be an oral GLP-1 but to be a better-tolerated one.
History & Discovery
ASC30 came out of Ascletis Pharma's small-molecule discovery programme in metabolic disease, first described publicly in a 2024 American Diabetes Association abstract as a potent, orally available non-peptide GLP-1 receptor biased agonist. Ascletis is a Hangzhou-based company listed in Hong Kong whose earlier work was in hepatitis C and B rather than metabolism. The clinical programme is notable for being run in the United States from the start — a departure from the pattern of Chinese biotechs developing domestically first and filing abroad later. The first-in-human oral study began in August 2024 and the subcutaneous study in September 2024, both under US investigational new drug applications with US-only sites. A first-in-human single-ascending-dose study was presented at the American Diabetes Association meeting in 2025, and the 28-day multiple-ascending-dose results at ObesityWeek in November 2025, reporting up to 6.5% placebo-adjusted weight loss over four weeks with no plateau. The 13-week oral phase 2a completed in December 2025 and was reported at the American Diabetes Association meeting in June 2026. A phase 2 in type 2 diabetes completed in August 2026. The company announced FDA phase 3 clearance on 3 August 2026 following positive end-of-phase-2 feedback, and dosed its first phase 3 participant on 30 August 2026, guiding to topline data in the third quarter of 2028 and a US filing by the end of that year. The competitive landscape moved sharply during that development window. When ASC30 entered the clinic, the oral GLP-1 field was wide open: oral semaglutide was approved only for type 2 diabetes, orforglipron was in phase 3, and Pfizer's danuglipron was still alive. By the time ASC30 reached phase 3, danuglipron had been discontinued over a liver injury in April 2025, oral semaglutide 25 mg had been approved for weight management in December 2025, and orforglipron had been approved in April 2026. Ascletis has also described fixed-dose combinations pairing ASC30 with its amylin and GIP-directed assets, all preclinical.
How It Works
GLP-1 drugs activate a receptor that lowers blood sugar and reduces appetite. That receptor sends two kinds of signal — one that produces the benefit, and one that both winds the receptor down and seems to contribute to nausea. ASC30 is designed to trigger only the first. It comes as a daily tablet and also as a long-acting injection that keeps working for weeks after a single dose.
ASC30 binds and activates the GLP-1 receptor with signalling the sponsor characterises as fully biased — engaging the Gs-cAMP pathway without recruiting β-arrestin. The cAMP arm drives the effects that make GLP-1 agonists useful: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying and central appetite suppression through hypothalamic and brainstem circuits. β-arrestin recruitment drives receptor internalisation and desensitisation and is implicated in some of the gastrointestinal burden. The rationale has independent support in the general case. Work modelling G-protein-biased agonism through GLP-1 receptor C-terminal mutations found that genetic changes reducing β-arrestin recruitment and slowing receptor internalisation can enhance signalling — conceptual support for using bias to improve efficacy, though that study used receptor mutations rather than biased ligands and says nothing about tolerability. A companion study comparing oppositely biased agonists in β-cells reported a mainly negative result on localisation: cAMP, PKA and ERK signalling is distributed widely across the cell with no major differences linkable to internalised versus surface receptor, while a β-arrestin-biased, fast-internalising agonist was an inefficient driver of both cAMP production and insulin secretion. Taken together these support the direction of the strategy while showing that biased-signalling outcomes are context- and cell-type-dependent. What is missing is ASC30-specific pharmacology. No published paper reports its cAMP EC50 or Emax, its β-arrestin recruitment, or a direct comparison against a balanced agonist. The claim rests on company conference material. The two formulations behave very differently in time. The oral tablet is dosed once daily with reported dose-proportional pharmacokinetics across 2 to 60 mg and a peak-to-trough ratio below 2:1 — a flat profile that is itself a plausible tolerability mechanism, independent of receptor bias, since it avoids the concentration spikes that provoke nausea. The subcutaneous depot has a reported observed half-life of 46 days in its treatment formulation and 75 days in its maintenance formulation, producing exposure that persists for months after a single injection.
Evidence Snapshot
Human Clinical Evidence
Phase 3 under way, with two completed randomised phase 2 studies behind it — but none of it peer-reviewed. The oral programme ran a phase 1 SAD/MAD study (72 participants), a 13-week phase 2a in obesity (125 participants, primary endpoint met at p<0.0001 across three doses) and a 13-week phase 2 in type 2 diabetes (100 participants, completed August 2026, topline not announced). The subcutaneous programme ran a phase 1/2 study (115 participants) whose phase 2 portion (65 participants) reported 24-week results. AURORA-1 and AURORA-2 are recruiting about 4,600 participants with 72-week primary endpoints and July 2028 completion.
Animal / Preclinical
Not independently assessable. GLP-1 receptor agonism is among the best-characterised pharmacology in metabolic medicine, but ASC30's own preclinical package has not been published — the discovery work exists as a 2024 American Diabetes Association abstract.
Mechanistic Rationale
Strong for GLP-1 receptor agonism, unverified for the biased-agonism claim specifically. Receptor biology is exceptionally well characterised and the therapeutic target is validated by multiple approved drugs. The proposition that reducing β-arrestin recruitment improves the efficacy-to-tolerability ratio has independent conceptual support and no confirmation in a controlled human comparison, for ASC30 or for any other compound.
Research Gaps & Open Questions
What the current literature has not yet settled about ASC30:
- 01Whether biased agonism actually improves tolerability. No head-to-head trial against a balanced GLP-1 agonist has been run, the phase 3 trials are placebo-controlled, and the company's comparison is a cross-trial table whose conclusion depends on which orforglipron titration schedule is chosen as comparator.
- 02ASC30's own receptor pharmacology. No published paper reports its cAMP EC50 or Emax or its β-arrestin recruitment, so the central mechanistic claim — fully biased, no β-arrestin recruitment — has never been independently verified.
- 03Absolute efficacy. Every weight-loss figure released is placebo-adjusted, and per-arm absolute percentages and sample sizes have not been disclosed for either formulation.
- 04The type 2 diabetes result. That phase 2 completed in August 2026 with HbA1c at week 13 as its primary endpoint and no topline has been announced, while phase 3 recruitment in a diabetes-inclusive population went ahead regardless.
- 05Durability. The longest oral dataset is 13 weeks and the longest depot dataset 24 weeks, both with the weight curve still falling at the end. Phase 3 reads out at 72 weeks in 2028.
- 06Body composition. No lean-mass or fat-mass data has been released for either formulation, which is now a routine question for obesity drugs and the reason bimagrumab-style combinations are being studied.
- 07Long-term hepatic safety, where the class has a specific and recent history and where ASC30's clean record so far comes from a few hundred participants over weeks.
- 08How the two formulations relate commercially — whether the depot is a differentiated product in its own right or a lifecycle extension, and whether its tolerability advantage over the tablet survives larger studies.
- 09Peer review. Nothing about ASC30 has been published in a peer-reviewed journal; the entire evidence base is company announcements, conference abstracts and one conference poster.
Forms & Administration
Two formulations in parallel development. The oral tablet is taken once daily and is the formulation carried into phase 3, with maintenance doses of 20, 40 and 60 mg reached through stepwise weekly titration from 1 mg; phase 3 uses longer titration periods of 12, 16 and 20 weeks for the three maintenance doses respectively, slower than phase 2, which the company expects to improve tolerability. The subcutaneous formulation is an ultra-long-acting depot given as a 400 mg injection once monthly with no titration and no weekly lead-in, with reported half-lives of 46 days (treatment formulation) and 75 days (maintenance formulation) supporting monthly dosing and possible quarterly maintenance. Neither formulation is commercially available.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Oral: maintenance doses of 20, 40 and 60 mg once daily, reached by stepwise titration from 1 mg. The type 2 diabetes phase 2 used 40, 60 and 80 mg. Subcutaneous depot: 400 mg per injection.
Frequency
Oral tablet once daily. Subcutaneous depot once monthly, with the company proposing quarterly maintenance dosing on the basis of its reported half-life.
Timing Considerations
Time of day
Once daily for the oral tablet; the published material does not specify a preferred time
Relative to meals
A food-effect assessment was included in the phase 1 oral study; results have not been released
Relative to exercise
Not tied to exercise timing.
The subcutaneous depot is given monthly without regard to timing, and its weeks-long half-life makes day-to-day timing irrelevant.
Cycle Length
Chronic and indefinite, as for all GLP-1 receptor agonists used for weight management — the phase 3 trials treat for 72 weeks.
Protocol Notes
ASC30 is not commercially available in any form and these figures describe trial protocols, not a prescribable regimen. The titration schedule is the part most likely to matter clinically, and it changed between phases. In the 13-week phase 2 all arms started at 1 mg with weekly steps — 1, 2, 5, 10, 15, 20 mg for the 20 mg arm, and longer ladders to reach 40 and 60 mg. Phase 3 deliberately slowed this down, using titration periods of 12, 16 and 20 weeks for the three maintenance doses, on the expectation that a gentler ramp reduces gastrointestinal events. That is a meaningful detail when reading the phase 2 tolerability numbers, because the adverse events clustered during titration rather than at maintenance, and it also means phase 3 tolerability should not be assumed to match phase 2. The subcutaneous depot works on an entirely different principle: a single 400 mg injection with no titration and no weekly lead-in, repeated monthly. In the phase 2 portion, participants received three monthly doses and were then observed without further dosing through week 24, with weight loss still separating from placebo four months after the last injection. That persistence is the formulation's selling point and also its main risk — a depot with a 46 to 75 day half-life cannot be withdrawn quickly.
ASC30 is an investigational drug in phase 3 trials, not approved by any regulator and not available outside those trials. Every efficacy figure published for it is placebo-adjusted and sponsor-reported rather than peer-reviewed.
Timeline of Effects
Onset
Weight loss begins within the first weeks on the oral tablet, though titration from 1 mg means therapeutic doses are not reached immediately — in phase 3 the ramp to a maintenance dose takes 12 to 20 weeks. The 28-day phase 1 multiple-ascending-dose study already showed up to 6.5% placebo-adjusted loss. For the subcutaneous depot, placebo-adjusted separation reached 2.7% by week 4 after a single injection.
Peak Effect
Not yet established, and the available data explicitly say so. Both the 28-day phase 1 and the 13-week phase 2 reported no observed plateau in weight loss at the end of the study period, meaning the curve was still descending when the trial stopped. For the depot, placebo-adjusted loss peaked at 7.5% at week 16 — eight weeks after the final injection — before easing to 5.8% at week 24. The phase 3 trials measure at week 72, which is the first timepoint likely to show where the effect actually settles.
After Discontinuation
This differs completely between the two formulations and is the clearest reason not to treat them as one drug. The oral tablet is a small molecule cleared over hours, so exposure ends within days of the last dose and weight regain would be expected to follow the pattern seen across the GLP-1 class. The subcutaneous depot has a reported half-life of 46 to 75 days: participants in the phase 2 portion were still 5.8% below placebo at week 24, four months after their third and final injection. Whether that is an advantage or a liability depends entirely on why someone is stopping.
Monitoring & Measurement
Bloodwork & Labs
- •Body weight and BMI — the primary endpoint in both phase 3 trials, measured as percent change from baseline
- •HbA1c and fasting glucose in participants with type 2 diabetes, the primary endpoint of the completed diabetes phase 2
- •ALT, AST and total bilirubin — the class-specific monitoring that matters most for oral small-molecule GLP-1 agonists, given that danuglipron and lotiglipron were both discontinued for liver injury
- •Lipid panel and blood pressure, both reported as improving across doses in the phase 2 programme though without disclosed figures
- •Amylase and lipase where pancreatitis is suspected, as for the class generally
Functional & Performance Tests
- •Waist circumference, a standard secondary measure in obesity trials
- •Proportion achieving 5%, 10% and 15% weight loss thresholds — the responder analysis that is usually more informative than mean change
- •ECG and QTc in early-phase work; no signal has been reported
- •Body composition by DXA would be the obvious addition, and notably has not been reported for either formulation
When to Test
In the trial programme, weight is tracked throughout with the primary assessment at week 72 in phase 3 and week 13 in the completed phase 2 studies. Liver enzymes are checked through titration and maintenance. For the subcutaneous depot, the phase 2 portion continued assessments to week 24, sixteen weeks after the final injection.
Interpretation & Notes
Two things are worth holding when reading any ASC30 number. The first is that every published efficacy figure is placebo-adjusted — the difference between the treatment arm and placebo, not the weight a participant actually lost. Placebo arms in obesity trials typically lose a little weight through trial participation alone, so the absolute figure is higher than the placebo-adjusted one, and because Ascletis has not released absolute values there is no way to say by how much. The second is that the gastrointestinal adverse-event rates come from a titration schedule that phase 3 has already abandoned in favour of a slower one. Events clustered during titration rather than maintenance, so a longer ramp should produce different numbers — which means the phase 2 tolerability profile is not a prediction of the phase 3 result in either direction.
Common Questions
What does 'biased agonism' mean for ASC30?
The GLP-1 receptor does not do one thing when activated. It couples to Gs proteins and raises cAMP, which drives glucose-dependent insulin secretion, glucagon suppression and central appetite suppression, and it also recruits β-arrestin, which drives receptor internalisation and desensitisation and is thought to contribute to the gastrointestinal burden. A biased agonist preferentially engages one arm. Ascletis's claim for ASC30 is unusually strong — a fully biased agonist without β-arrestin recruitment, rather than merely cAMP-preferring. The supporting receptor pharmacology has never been published, so that claim rests on company posters. Independent work supports the premise in general terms: reducing β-arrestin recruitment and slowing receptor internalisation can enhance GLP-1 receptor signalling. Whether it translates into a meaningful tolerability advantage in people is the open question the phase 3 programme will answer.
What stage is ASC30 actually at?
Phase 3, since late August 2026. Two global trials are recruiting: AURORA-1 (NCT07743463) in about 3,003 adults with obesity or overweight with weight-related comorbidities, and AURORA-2 (NCT07743450) in about 1,560 adults who also have type 2 diabetes. Both test maintenance doses of 20, 40 and 60 mg once daily against placebo, both use percent change in body weight at week 72 as the primary endpoint, and both are scheduled to complete in July 2028. Sites span the United States, United Kingdom, Canada, Germany, Poland, Czechia and Greece. The company has said it received phase 3 clearance from the FDA following positive end-of-phase-2 feedback, dosed its first participant on 30 August 2026, and expects topline data in the third quarter of 2028 with a US filing by the end of that year.
Is ASC30 a tablet or an injection?
Both, and keeping them apart matters because their numbers get mixed up constantly. The oral tablet is once daily, is the formulation in phase 3, and produced placebo-adjusted weight loss of 7.7% at 60 mg over 13 weeks. The subcutaneous version is an ultra-long-acting depot given as a 400 mg injection once a month with no titration, and in its phase 2 portion produced placebo-adjusted loss of 7.5% at week 16; its reported half-life is 46 days for the treatment formulation and 75 days for the maintenance formulation, which is why the company talks about monthly dosing with quarterly maintenance. Weight loss was still 5.8% below placebo at week 24, four months after the last injection. A 7.7% figure and a 7.5% figure that look almost identical therefore describe entirely different products, schedules and timepoints.
Does the biased-agonism claim hold up on tolerability?
It is consistent with the data and not demonstrated by it. In the 13-week oral phase 2, all-grade vomiting ran 22%, 25% and 30% across the 20, 40 and 60 mg arms, and nausea 49%, 63% and 40% — the non-monotonic nausea pattern is as the company reported it. All gastrointestinal events were grade 1 or 2, concentrated during titration, with no grade 3 or higher events and no drug-related serious adverse events. Discontinuations for adverse events were 4.8% overall, and notably 0% in the 60 mg arm against 7.3% and 7.5% in the lower-dose arms. There was no hepatic signal, which matters in this class: Pfizer abandoned danuglipron in April 2025 after a liver injury and had dropped lotiglipron for the same reason in 2023. But the comparison Ascletis draws is a cross-trial table, not a head-to-head, and it is sensitive to which orforglipron dataset is chosen — against orforglipron with a slower every-four-week titration, ASC30 shows no clear advantage. The subcutaneous depot has the cleanest safety data in the programme: no adverse-event discontinuations at all and all gastrointestinal events grade 1.
How does it compare with orforglipron and oral semaglutide?
It is now behind both, which changes the question it has to answer. Orforglipron was approved by the FDA on 1 April 2026 as Foundayo, a once-daily oral GLP-1 receptor agonist for weight management. Oral semaglutide 25 mg was approved on 22 December 2025 as a Wegovy tablet, the first oral GLP-1 for weight management — distinct from Rybelsus, which is the oral semaglutide product for type 2 diabetes and is often confused with it. Both reached the market while ASC30 was in phase 2. No head-to-head trial against either exists or is planned publicly, and ASC30's phase 3 trials are placebo-controlled. The differentiation ASC30 is pursuing is therefore tolerability and, in the subcutaneous formulation, a dosing interval neither competitor offers.
Who ASC30 Is NOT For
- •Pregnancy and breastfeeding — excluded from the trial programme and no safety data exists.
- •Children and adolescents — the entire programme is in adults.
- •Personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2, carried as a class consideration from approved GLP-1 receptor agonists.
- •History of pancreatitis.
- •Severe gastroparesis or clinically significant gastric-emptying abnormality, which is also a trial exclusion criterion across this class.
- •Known hypersensitivity to the compound or its excipients.
- •Significant hepatic impairment or unexplained transaminase elevation warrants particular caution with oral small-molecule GLP-1 agonists, given that two compounds in this class have been discontinued for drug-induced liver injury.
- •For the subcutaneous depot specifically, any situation where rapid withdrawal of drug exposure might be needed — a 46 to 75 day half-life does not allow it.
Drug & Supplement Interactions
No dedicated interaction studies have been published. What follows is class-level and mechanistic. The two considerations that matter for every GLP-1 receptor agonist apply here. Slowed gastric emptying can alter the absorption of co-administered oral drugs, which is most consequential for narrow-therapeutic-index medicines and for oral contraceptives; this effect is generally largest during titration, when gastric emptying slows most. And combination with insulin or sulfonylureas raises hypoglycaemia risk, because the GLP-1 agonist's own insulinotropic effect is glucose-dependent but the partner drug's is not, so dose reduction of the secretagogue is the usual approach. Two things are specific to this compound rather than the class. ASC30 is a small molecule rather than a peptide, so unlike semaglutide or tirzepatide it has the potential for cytochrome P450 and transporter-mediated interactions — none have been published, and this is a genuine information gap rather than a reassurance. And because an oral small-molecule GLP-1 agonist is being given to a population that will often also be taking statins, antihypertensives and metformin, the absence of published interaction data is more consequential than it would be for an injectable. The subcutaneous depot raises a different question. With a half-life of 46 to 75 days, any interaction established in future would persist for months after the last injection, and the usual clinical remedy of stopping the drug is unavailable.
Safety Profile
Common Side Effects
Cautions
- • Investigational. ASC30 is not approved anywhere and is available only through registered clinical trials.
- • All efficacy and safety figures are sponsor-reported from press releases, conference abstracts and a conference poster. None has been peer-reviewed, and absolute weight-change numbers have never been released — every efficacy figure is placebo-adjusted.
- • Standard GLP-1 class precautions apply, including the thyroid C-cell tumour warning carried by approved agents in the class, pancreatitis, and gallbladder events.
- • Liver safety deserves specific attention for oral small-molecule GLP-1 agonists as a class: Pfizer discontinued danuglipron in April 2025 after a drug-induced liver injury and lotiglipron in 2023 for the same reason. ASC30 has reported no hepatic signal across its phase 1 and phase 2 studies, which is reassuring but comes from a few hundred participants over weeks rather than years.
- • The type 2 diabetes phase 2 study completed in August 2026 and no topline result has been announced, while the phase 3 programme including a diabetes population began before that readout would have been public.
- • The subcutaneous depot's 46 to 75 day half-life means exposure cannot be withdrawn quickly — relevant if an adverse event, pregnancy or surgery intervenes.
What We Don't Know
Whether biased agonism delivers a tolerability advantage that survives a controlled comparison, which no trial has attempted. Absolute rather than placebo-adjusted efficacy. Durability past 24 weeks for the depot and past 13 weeks for the tablet, which phase 3 will address at 72 weeks. Long-term hepatic safety. The diabetes result. Body-composition effects — no lean-mass data has been released for either formulation, which is now a standard question for any obesity drug. And the receptor pharmacology itself: no published paper quantifies ASC30's cAMP or β-arrestin activity, so the central mechanistic claim is unverified outside the company.
Legal Status
United States
Investigational. ASC30 is not FDA-approved for any indication and is available only through registered clinical trials. The company reported receiving FDA clearance to begin phase 3 in August 2026 and has guided to a US new drug application by the end of 2028.
International
Investigational everywhere. The development programme is led from the United States under US investigational new drug applications, with phase 3 sites added across the United Kingdom, Canada, Germany, Poland, Czechia and Greece. No Chinese registration trial for ASC30 has been identified despite the sponsor being a Chinese company, and the company has guided to a European filing in early 2029.
Sports & Competition
Not named on the WADA Prohibited List — GLP-1 receptor agonists as a class appear nowhere on the 2027 List, and the metabolic modulators in S4.4 cover AMPK activators, PPARδ agonists, Rev-erbα agonists, insulins and insulin mimetics rather than incretins. But absence from the List is not the end of the analysis: S0 prohibits at all times any pharmacological substance not addressed elsewhere and with no current approval by any governmental regulatory health authority for human therapeutic use, explicitly including drugs under clinical development. ASC30 is in phase 3 and approved nowhere, so S0 applies to it. That would change if it is approved, at which point it would be treated like other approved GLP-1 agonists, which are not prohibited.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
ASC30 is a peptide.
Reality
It is a small molecule that binds the GLP-1 receptor. It is included in this catalogue because it competes directly with peptide GLP-1 agonists and sits in the same therapeutic space, the same reason orforglipron is included. The distinction is not pedantic: being a small molecule is what makes oral dosing straightforward, and it is also why cytochrome P450 and transporter interactions are a live question for ASC30 in a way they are not for semaglutide.
Myth
Biased GLP-1 agonists eliminate GI side effects.
Reality
The hypothesis is reduction, not elimination, and the ASC30 data show why the distinction matters. In the 13-week phase 2, nausea still occurred in 40 to 63% of participants and vomiting in 22 to 30%, depending on dose. What the data do show is that the events were grade 1 or 2, concentrated during titration, and produced no discontinuations at all in the 60 mg arm. Whether that profile is better than a well-titrated balanced agonist has never been tested head to head.
Myth
ASC30 is in phase 2.
Reality
It moved to phase 3 in late August 2026. Two global trials, AURORA-1 and AURORA-2, are recruiting roughly 4,600 participants in total across the US, UK, Canada and four European countries, both with percent change in body weight at week 72 as the primary endpoint and completion estimated for July 2028. The company reported FDA phase 3 clearance on 3 August 2026 and first participant dosing on 30 August 2026.
Myth
The 7.7% and 7.5% figures are consistent results from the same programme.
Reality
They come from different drugs in every practical sense. The 7.7% is placebo-adjusted weight loss at week 13 on a 60 mg once-daily oral tablet. The 7.5% is placebo-adjusted weight loss at week 16 after three monthly 400 mg subcutaneous depot injections. Different formulation, different dose unit, different schedule, different timepoint, different trial. The numerical coincidence is the reason this confusion is so common.
Myth
ASC30 would be the first oral GLP-1 for weight loss.
Reality
That race finished while ASC30 was in phase 2. Oral semaglutide 25 mg was approved as a Wegovy tablet on 22 December 2025, and orforglipron was approved as Foundayo on 1 April 2026. ASC30 is now competing on tolerability and, in its injectable formulation, on dosing interval — not on being first. It is also worth not confusing the oral semaglutide products: Rybelsus is the type 2 diabetes tablet approved in 2019; the weight-management tablet is a separate, higher-dose product.
Myth
Phase 2 results from a company press release are equivalent to published trial data.
Reality
They are not, and for ASC30 this is the whole evidential picture rather than a footnote. Nothing about the compound has appeared in a peer-reviewed journal. The strongest sources are American Diabetes Association abstracts, which are editorially screened rather than peer reviewed, plus an ObesityWeek poster and company announcements. Absolute efficacy figures, per-arm sample sizes and the full adverse-event tables have not been released. That is normal for a programme at this stage — it is also the reason confidence in the numbers should be lower than their precision suggests.
Published Research
18 studiesHRS-7535, an oral small-molecule GLP-1 receptor agonist, in Chinese adults with obesity without diabetes: a randomized, double-blind, placebo-controlled phase 2 trial
Gu W et al., Nature Communications 2026. The closest published analogue to ASC30 — a China-originated oral small-molecule GLP-1 receptor agonist with peer-reviewed phase 2 data, reporting clinically meaningful weight loss at 60 mg daily and above. Useful precisely because ASC30's own phase 2 results have not been published, so this is what the same class looks like when it clears peer review.
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms
Modelling G protein-biased agonism using GLP-1 receptor C-terminal mutations
Tran HD et al., Molecular Metabolism 2026. Conceptual support for the strategy ASC30 pursues: genetic changes that reduce β-arrestin recruitment and slow GLP-1 receptor internalisation can enhance receptor signalling. Two limits worth carrying — it uses receptor mutations rather than biased ligands, and it says nothing about gastrointestinal tolerability, which is the claim ASC30 is actually marketed on.
Spatially diffuse cAMP signalling with oppositely biased GLP-1 receptor agonists in β-cells despite differences in receptor localisation
Chen S et al., Molecular Metabolism 2026. Largely a negative result on the localisation hypothesis — cAMP, PKA and ERK signalling is distributed widely across β-cells with no major differences attributable to internalised versus surface receptor. The finding that does support the biased strategy is secondary: a β-arrestin-biased, fast-internalising agonist proved an inefficient driver of both cAMP production and insulin secretion.
Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son JW et al., Endocrine Reviews 2026. The current map of the incretin pipeline, which is the context that matters most for ASC30 — it entered a field that gained two approved oral GLP-1 agonists while it was in phase 2, and the review places oral small molecules against amylin combinations, triple agonists and the GIP agonism-versus-antagonism question.
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
Tirzepatide Once Weekly for the Treatment of Obesity
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
AURORA-1: Phase III study of once-daily oral ASC30 in adults with obesity or overweight with weight-related comorbidities (NCT07743463)
Recruiting since 31 August 2026, about 3,003 participants, maintenance doses of 20, 40 and 60 mg against placebo, primary endpoint percent change in body weight at week 72, completion estimated July 2028. Sites in the US, UK, Canada, Germany, Poland, Czechia and Greece. This record and its companion are the primary evidence that ASC30 is in phase 3, since no publication reports it.
AURORA-2: Phase III study of once-daily oral ASC30 in adults with obesity or overweight with type 2 diabetes (NCT07743450)
Phase IIa study of ASC30 tablets in participants with obesity or overweight with weight-related comorbidities (NCT07002905)
Phase II study of ASC30 tablets in participants with type 2 diabetes mellitus (NCT07321678)
Phase I/IIa study of ASC30 injection for subcutaneous use in participants with obesity (NCT06679959)
Phase I study of ASC30 tablets in participants with obesity (NCT06680440)
1672-P: Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity
American Diabetes Association Scientific Sessions, June 2026. The 13-week oral phase 2a result: placebo-adjusted weight reduction of 5.4%, 7.0% and 7.7% at 20, 40 and 60 mg, all p<0.0001. Conference abstracts are editorially screened rather than peer-reviewed, and absolute per-arm figures were not disclosed — so this is the highest-quality source that exists for ASC30's efficacy, which is itself the point.
750-P: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity — A First-in-Human Single Ascending Dose Study
764-P: Discovery of ASC30, a Highly Potent and Orally Available Novel Nonpeptide GLP-1 Receptor Biased Agonist
Quick Facts
- Class
- Small-Molecule Biased GLP-1R Agonist
- Tier
- C
- Evidence
- Moderate
- Safety
- Limited Data
- Updated
- Oct 2026
- Citations
- 18PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.